NCT03998709View on ClinicalTrials.gov

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 1, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

July 31, 2022

Conditions
Healthy
Interventions
DRUG

Somatostatin

Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study

OTHER

Dextrose

intravenous glucose will be used to raise fasting glucose in people with NFG / NGT

DRUG

Insulin

insulin will be used to lower fasting FFA and glucose in people with IFG / IGT

OTHER

Intralipid

intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER

NCT03998709 - Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion | Biotech Hunter | Biotech Hunter